Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV

(2020) Jia Liu et al.   JOURNAL OF MEDICAL VIROLOGY

Early lessons from the frontline of the 2019-nCoV outbreak

(2020) Hong Zhang   LANCET

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

(2020) Clark D Russell et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

First Case of 2019 Novel Coronavirus in the United States

(2020) Michelle L. Holshue et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

(2020) Timothy P. Sheahan et al.   Nature Communications

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

(2020) Hongzhou Lu   BioScience Trends

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

(2020) Jianjun Gao et al.   BioScience Trends

Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection

(2019) Abdulrahman Mohammed G. Habib et al.   BMC INFECTIOUS DISEASES

A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics

(2019) Sabue Mulangu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

(2018) Yaseen M. Arabi et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

(2018) Maria L. Agostini et al.   mBio

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

(2017) François Ferron et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

(2017) Timothy P. Sheahan et al.   Science Translational Medicine

Dynamic changes in CD45RA−Foxp3high regulatory T-cells in chronic hepatitis C patients during antiviral therapy

(2016) Zhiqin Li et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

A review of treatment modalities for Middle East Respiratory Syndrome

(2016) Yin Mo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome: a case report

(2015) Uh Jin Kim et al.   ANTIVIRAL THERAPY

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

(2014) A. Hill et al.   CLINICAL INFECTIOUS DISEASES

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study

(2014) Ali S Omrani et al.   LANCET INFECTIOUS DISEASES

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

(2013) Darryl Falzarano et al.   Scientific Reports

Ribavirin modulates the conversion of human CD4+ CD25−T cell to CD4+ CD25+ FOXP3+T cell via suppressing interleukin-10-producing regulatory T cell

(2012) Tamaki Kobayashi et al.   IMMUNOLOGY

Cell Type Mediated Resistance of Vesicular Stomatitis Virus and Sendai Virus to Ribavirin

(2010) Nirav R. Shah et al.   PLoS One